Skip to main content
Default Image

Insulin: a case study for why we need a public option in the pharmaceutical industry

The private pharmaceutical industry has every incentive to game the patent system, extract the highest prices it can, and delay the market entry of competitor drugs as long as possible. With the largest lobby in Washington and a well-oiled revolving door to its regulators — hello, Alex Azar! — large pharmaceutical companies have deftly evaded attempts to rein in their excesses. In addition to having potentially catastrophic effects on the lives of patients, profit-maximizing strategies responsible for these eye-watering price tags also result in differential pricing practices with discriminatory effects, unnecessary financial strain on the U.S. health care system, and contribute to growing corporate power over our democracy. But as one of us (D.B.) argues in a report released Tuesday, if we act now to institute a public option for pharmaceuticals, we could ensure that this terrible story is never repeated.

Publication date: 2019-09-09
Parent publication: STAT
Publication URL: https://www.statnews.com/2019/09/10/insulin-public-option-pharmaceutical-industry/

More related work

Medicine Cost

Americans deserve publicly owned generic drugs

Bold policies could have saved America’s largest generic drug plant, but it’s never too late to start putting communities first.

read more
Illustration courtesy of United Nations

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. But the COVID-19

read more
Neil McInroy (Source: Coop News)

Neil McInroy joins TDC to advise stepped-up community wealth building program

The former CEO of a leading UK economic think tank will be central in helping build capacity to offer powerful new technical assistance to cities and local authorities pursuing community wealth building strategies.

read more